ResMed (RMD) Stock Price & Analysis

RMD$239.53+0.64 +0.27%
Medical - Instruments & SuppliesLarge CapHigh Quality
Compare
Market cap$33.69BEnterprise value$33.56BRevenue (TTM)$5.73BMarket positionTop 25%

Score

61
Neutral
Value
48
Quality
86
Growth
48

AI Analysis

Snapshot

ResMed looks like a quality compounder first — Quality 86/100 and an overall 61/100. Under the hood: P/E 22.0, about 44% below its own multi-year median, plus revenue compounding ~10% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

48
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

48
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

86
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

ResMed Inc. (RMD) last printed $239.53. Equity value is $33.69B. Trailing earnings multiple 21.15. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2017201820192020202120222023202420252026
$2.07B$2.34B$2.61B$2.96B$3.2B$3.58B$4.22B$4.69B$5.15B$5.65B

About

ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.

ResMed (RMD) Stock Price & Analysis

RMD price $239.53 +0.64 +0.27%

Ticker
RMD
Price
$239.53
Change
+0.64 +0.27%
Market cap
$33.69B
P/E
21.15
Forward P/E
19.48
Dividend yield
1.04%
Beta
0.76
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Stocklytics score
61
Value
48
Quality
86
Growth
48

Stocklytics score rationale: value 48, quality 86, growth 48.

AI Score 75. ResMed Inc. has a solid market capitalization of approximately $32.34 billion and a strong net profit margin of 27.79%, indicating effective cost management

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener